DexCom earnings beat by $0.03, revenue topped estimates
Saba Capital Management, L.P., a significant shareholder in abrdn Life Sciences Investors (NYSE:HQL), recently sold 15,400 shares of common stock. The company, currently valued at $333.37 million, offers an impressive 15.91% dividend yield and has shown strong recent momentum with an 8.74% return over the past week. The transaction, executed on April 14, 2025, was completed at a price of $11.67 per share, resulting in a total sale value of approximately $179,718. Following this sale, Saba Capital Management retains ownership of 3,078,916 shares in the company. The transaction was disclosed in a recent SEC filing, underscoring the ongoing portfolio adjustments by the investment firm. InvestingPro analysis reveals several more key insights about HQL’s financial health and market position, with 6 additional ProTips available to subscribers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.